Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...

Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, today announced ...

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the first patient ...

However, the full potential of PD-1 blockade therapy remains unrealized, as response rates are still low across many cancer types. Interleukin-2 (IL-2)-based immunotherapies hold promise, as they can ...

The therapy, a fully human monoclonal antibody, targets a newly identified immune checkpoint protein that could enhance ...

Researchers from the VIB-KU Leuven Center for Cancer Biology, in collaboration with other scientists, have discovered a way ...

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

Biosciences announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease ...

ARC101 is the company's first bispecific antibody targeting Claudin 6 (CLDN6), optimized for best-in-class T cell engagement ...

An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...

Iontra will show an extended cycle life improvement using a Veken Pouch Cell (3.2Ah, LCO/GR Chemistry), a Pluto-1S50 module, ...